The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D.
Passot C, et al. Among authors: paintaud g.
MAbs. 2016 Oct;8(7):1407-1416. doi: 10.1080/19420862.2016.1216741. Epub 2016 Aug 9.
MAbs. 2016.
PMID: 27589009
Free PMC article.